RABEPRAZOLE SODIUM and DYSPNOEA

1,159 reports of this reaction

2.0% of all RABEPRAZOLE SODIUM reports

#9 most reported adverse reaction

Overview

DYSPNOEA is the #9 most commonly reported adverse reaction for RABEPRAZOLE SODIUM, manufactured by Waylis Therapeutics LLC. There are 1,159 FDA adverse event reports linking RABEPRAZOLE SODIUM to DYSPNOEA. This represents approximately 2.0% of all 58,263 adverse event reports for this drug.

Patients taking RABEPRAZOLE SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DYSPNOEA1,159 of 58,263 reports

DYSPNOEA is a less commonly reported adverse event for RABEPRAZOLE SODIUM, but still significant enough to appear in the safety profile.

Other Side Effects of RABEPRAZOLE SODIUM

In addition to dyspnoea, the following adverse reactions have been reported for RABEPRAZOLE SODIUM:

CHRONIC KIDNEY DISEASE — 4,877 reports
RENAL FAILURE — 3,419 reports
ACUTE KIDNEY INJURY — 2,604 reports
NAUSEA — 1,619 reports
DRUG INEFFECTIVE — 1,541 reports
END STAGE RENAL DISEASE — 1,309 reports
PAIN — 1,173 reports
DIARRHOEA — 1,165 reports
DEATH — 1,123 reports
TUBULOINTERSTITIAL NEPHRITIS — 1,118 reports

Other Drugs Associated with DYSPNOEA

The following drugs have also been linked to dyspnoea in FDA adverse event reports:

0XYGEN ABEMACICLIB ABIRATERONE ACETATE ACALABRUTINIB ACETAMINOPHEN ACETAMINOPHEN 325 MG ACETAMINOPHEN 325MG ACETAMINOPHEN 500 MG ACETAMINOPHEN 500MG ACETAMINOPHEN AND CODEINE PHOSPHATE ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR, GUAIFENESIN, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE

Frequently Asked Questions

Does RABEPRAZOLE SODIUM cause DYSPNOEA?

DYSPNOEA has been reported as an adverse event in 1,159 FDA reports for RABEPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DYSPNOEA with RABEPRAZOLE SODIUM?

DYSPNOEA accounts for approximately 2.0% of all adverse event reports for RABEPRAZOLE SODIUM, making it a notable side effect.

What should I do if I experience DYSPNOEA while taking RABEPRAZOLE SODIUM?

If you experience dyspnoea while taking RABEPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

RABEPRAZOLE SODIUM Full Profile All Drugs Causing DYSPNOEA Waylis Therapeutics LLC Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.